Correlates of human papillomavirus vaccine coverage: A state-level analysis

Sexually Transmitted Diseases

Volumn 42, Issue 2, 2015, Pages 71-75

  Moss, Jennifer L ^a   Reiter, Paul L ^b   Brewer, Noel T ^a  

^a IL   (United States)

^b THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE;

ADOLESCENT; ANUS CANCER; ARTICLE; CANCER INCIDENCE; CANCER MORTALITY; FEMALE; HEALTH CARE SYSTEM; HUMAN; MALE; NEOPLASM; RACE; SEX DIFFERENCE; UNITED STATES; UTERINE CERVIX CANCER; VACCINATION; VAGINA CANCER; VULVA CANCER; ANUS NEOPLASMS; ATTITUDE TO HEALTH; CLINICAL TRIAL; COST BENEFIT ANALYSIS; ECONOMICS; INCIDENCE; MASS SCREENING; MULTICENTER STUDY; PAPILLOMAVIRUS INFECTIONS; PATIENT ATTITUDE; PATIENT SELECTION; PREVENTIVE HEALTH SERVICE; PUBLIC HEALTH; STATISTICS AND NUMERICAL DATA; UTERINE CERVICAL NEOPLASMS;

ADOLESCENT; ANUS NEOPLASMS; COST-BENEFIT ANALYSIS; FEMALE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; IMMUNIZATION PROGRAMS; INCIDENCE; MALE; MASS SCREENING; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PATIENT ACCEPTANCE OF HEALTH CARE; PATIENT SELECTION; PUBLIC HEALTH; SEX FACTORS; UNITED STATES; UTERINE CERVICAL NEOPLASMS; VACCINATION;

EID: 84921895594     PISSN: 01485717     EISSN: 15374521     Source Type: Journal    
DOI: 10.1097/OLQ.0000000000000225     Document Type: Article

References (32)

1. Centers for Disease Control and Prevention (CDC). Recommendations and guidelines: Advisory Committee on Immunization Practices. Available at: http://www.cdc.gov/vaccines/acip/index.html. Accessed March 8, 2013.
2. Department of Health and Human Services. Immunization and infectious diseases. Available at: http://healthypeople.gov/2020/topicsobjectives2020/objectiveslist.aspx?topicId=23. Updated 2012.
3. Centers for Disease Control and Prevention (CDC). National and state vaccination coverage among adolescents aged 13-17 years-United States, 2012. MMWR Morb Mortal Wkly Rep 2013; 62: 685-693.
4. Markowitz LE, Hariri S, Lin C, et al. Reduction in human papillomavirus (HPV) prevalence among young women following HPV vaccine introduction in the United States, National Health and Nutrition Examination Surveys, 2003-2010. J Infect Dis 2013; 208: 385-393 doi: 10.1093/infdis/jit192.
5. Flagg EW, Schwartz R, Weinstock H. Prevalence of anogenital warts among participants in private health plans in the United States, 2003-2010: Potential impact of human papillomavirus vaccination. Am J Public Health 2013; 103:1428-1435. doi: 10.2105/AJPH.2012.301182.
6. Tabrizi SN, Brotherton JM, Kaldor JM, et al. Fall in human papillomavirus prevalence following a national vaccination program. J Infect Dis 2012; 206:1645-1651. doi: 10.1093/infdis/jis590.
7. Bach PB. Gardasil: From bench, to bedside, to blunder. Lancet 2010; 375:963-964. doi: 10.1016/S0140-6736(09)62029-8.
8. Centers for Disease Control and Prevention (CDC). United States Cancer Statistics: Public information data. Available at: http://wonder. cdc.gov/cancer.HTML. Updated 2014. Accessed June 9, 2014.
9. Centers for Disease Control and Prevention (CDC). FDA licensure of bivalent human papillomavirus vaccine (HPV2, cervarix) for use in females and updated HPV vaccination recommendations from the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2010; 59:626-629.
10. Centers for Disease Control and Prevention (CDC). FDA licensure of quadrivalent human papillomavirus vaccine (HPV4, gardasil) for use in males and guidance from the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2010; 59:630-632.
11. Gillison ML, Chaturvedi AK, Lowy DR. HPV prophylactic vaccines and the potential prevention of noncervical cancers in both men and women. Cancer 2008; 113(10 suppl):3036-3046. doi: 10.1002/cncr.23764.
12. U.S. Census Bureau. National, state, and Puerto Rico commonwealth total datasets: Population, population change, and estimated components of population change: April 1, 2010 to July 1, 2013. Available at: http://www.census.gov/popest/data/national/totals/2013/NST-EST2013-alldata.html. Updated 2014. Accessed June 9, 2014.
13. U.S. Census Bureau. American FactFinder. Available at: http://factfinder2.census.gov/faces/nav/jsf/pages/index.xhtml. Updated 2014. Accessed June 9, 2014.
14. U.S. Bureau of Labor Statistics. Occupational employment statistics. http://data.bls.gov/oes/. Accessed June 9, 2014.
15. Child and Adolescent Health Measurement Initiative. The National Survey of Children's Health. Available at: http://childhealthdata.org/learn/NSCH. Updated 2012. Accessed June 9, 2014.
16. Brener ND, Wheeler L,Wolfe LC, et al. Health services: Results from the School Health Policies and Programs Study 2006. J Sch Health 2007; 77:464-485. doi: 10.1111/j.1746-1561.2007.00230.x.
17. School-based Health Alliance.2010-2011 Census report of school-based health centers. 2012
18. Centers for Disease Control and Prevention (CDC). Behavioral Risk Factor Surveillance System. Available at: http://www.cdc.gov/brfss/. Updated 2014. Accessed June 9, 2014.
19. Caplan LS, McQueen DV, Qualters JR, et al. Validity of women's self-reports of cancer screening test utilization in a managed care population. Cancer Epidemiol Biomarkers Prev 2003; 12(11 Pt 1): 1182-1187.
20. Pizarro J, Schneider TR, Salovey P. A source of error in self-reports of Pap test utilization. J Community Health 2002; 27:351-356.
21. Johnson TP, O'Rourke DP, Burris JE, et al. An investigation of the effects of social desirability on the validity of self-reports of cancer screening behaviors. Med Care 2005; 43:565-573. doi: 00005650-200506000-00007.
22. Rauscher GH, Johnson TP, Cho YI, et al. Accuracy of self-reported cancer-screening histories: A meta-analysis. Cancer Epidemiol Biomarkers Prev 2008; 17:748-757. doi: 10.1158/1055-9965. EPI-07-2629.
23. Centers for Disease Control and Prevention (CDC). STD facts. Available at: http://www.cdc.gov/std/hpv/stdfact-hpv.htm. Updated 2013. Accessed January 14, 2014.
24. Adimora AA, Schoenbach VJ. Social context, sexual networks, and racial disparities in rates of sexually transmitted infections. J Infect Dis 2005; 191(suppl 1):S115-S122. doi: JID32102.
25. Doherty IA, Padian NS, Marlow C, et al. Determinants and consequences of sexual networks as they affect the spread of sexually transmitted infections. J Infect Dis 2005; 191(suppl 1):S42-S54. doi: JID32098.
26. Laumann EO, Youm Y. Racial/ethnic group differences in the prevalence of sexually transmitted diseases in the United States: A network explanation. Sex Transm Dis 1999; 26:250-261.
27. WatsonM, Saraiya M, BenardV, et al. Burden of cervical cancer in the United States, 1998-2003. Cancer 2008; 113(10 suppl):2855-2864. doi: 10.1002/cncr.23756.
28. Goldie SJ, Kohli M, Grima D, et al. Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. J Natl Cancer Inst 2004; 96(8):604-615.
29. Chesson HW, Ekwueme DU, Saraiya M, et al. The cost-effectiveness of male HPV vaccination in the United States. Vaccine 2011; 29: 8443-8450. doi: 10.1016/j.vaccine.2011.07.096.
30. Elbasha EH, Dasbach EJ, Insinga RP. Model for assessing human papillomavirus vaccination strategies. Emerg Infect Dis 2007; 13: 28-41. doi: 10.3201/eid1301.060438.
31. Armstrong EP. Prophylaxis of cervical cancer and related cervical disease: A review of the cost-effectiveness of vaccination against oncogenic HPV types. J Manag Care Pharm 2010; 16:217-230. doi: 2010(16)3: 217-230.
32. Rand CM, Shone LP, Albertin C, et al. National health care visit patterns of adolescents: Implications for delivery of new adolescent vaccines. Arch Pediatr Adolesc Med 2007; 161:252-259. doi: 10.1001/archpedi.161.3.252.